FDA-Approved vs. Compounded GLP-1 Medications: What's the Difference?

If you research GLP-1 medications online, you'll see both "FDA-approved" and "compounded" options, often at very different prices. They are not the same thing. This guide explains the difference using the FDA's own published statements.

What "FDA-approved" means

An FDA-approved drug, such as Wegovy (semaglutide) or Zepbound (tirzepatide), has been reviewed by the FDA for safety, effectiveness, and quality before it is marketed, and it comes with FDA-reviewed prescribing information and a Medication Guide.

What "compounded" means

Compounding is when a pharmacy prepares a medication that is not an FDA-approved product. The FDA states that compounded drugs are not FDA-approved and that the agency does not review them for safety, effectiveness, or quality before they are marketed.

The FDA also says a compounded drug might be appropriate if a patient's medical need cannot be met by an FDA-approved drug, or if the approved drug is not commercially available. It recommends that compounded drugs be used only in patients whose medical needs cannot be met by an FDA-approved drug.

What the FDA says about compounded GLP-1 drugs

From the FDA's page "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (current as of October 1, 2026):

• Dosing errors. The FDA has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide. These involved patients measuring incorrect doses and, in some cases, health care professionals miscalculating doses. The FDA has also received reports that may be related to doses beyond what's in the approved labeling.
• Multi-dose vials. The FDA generally recommends that multi-dose vials of sterile medications be used within 28 days of first use, because the risk of contamination increases afterward, and it advises using a new, sterile needle and syringe for each dose.
• Storage during shipping. Injectable GLP-1 drugs require refrigeration. The FDA has received complaints of compounded products arriving warm or with inadequate ice packs, and it recommends not using an injectable GLP-1 drug that arrives warm or insufficiently refrigerated.
• Salt forms. Some compounded semaglutide products may use salt forms (such as semaglutide sodium or acetate), which the FDA says are different active ingredients from those in approved drugs. The FDA says it is not aware of a lawful basis for their use in compounding.
• Unapproved ingredients. The FDA says retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any condition.
• Fraudulent products. The FDA is aware of fraudulent compounded semaglutide and tirzepatide with false label information, including labels naming pharmacies that do not exist or that did not compound the product.
• Adverse event reports. As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The FDA notes that adverse events from these products are likely underreported and that it is not always possible to tell whether an event was caused by the drug.

Illegally marketed products

The FDA also warns about:

• Counterfeit Ozempic in the U.S. market.
• Products labeled "for research purposes" or "not for human consumption" that are sold to consumers for human use with dosing instructions. The FDA urges consumers not to buy them.
• Illegal online sales of semaglutide and tirzepatide. The FDA urges consumers to buy only from state-licensed pharmacies.

FDA's telehealth red flags for consumers

The FDA lists these warning signs for a telehealth company:

• Claims that a compounded drug is the same as an FDA-approved drug
• Medicine offered at deep discounts or prices that seem too good to be true
• Medicine that looks different from what you've previously received or from what the website shows, or that arrives damaged or without instructions for use
• No screening and prescription from a licensed doctor before providing medicine
• No licensed doctor available to answer questions after you receive the medication
• Spelling errors on the label or incorrect pharmacy addresses
• A pharmacy name on the label that may be fraudulent

Marketing enforcement

The FDA has sent warning letters to telehealth companies over how they market compounded GLP-1 products, including claims that describe compounded products as equivalent to approved drugs. The FDA's warning letters page lists current actions.

Key differences at a glance

Questions to ask a provider

1. Is the medication I would receive FDA-approved or compounded?
2. If compounded, why can't an FDA-approved product meet my medical needs?
3. Which state-licensed pharmacy prepares and ships it, and how can I verify that?
4. What is the exact ingredient and strength, and how will I measure and inject each dose?
5. How should the medication be stored, and for how long can I use a vial once opened?
6. Who can I contact with questions after the medicine arrives, and how do I report a problem?

How to report a problem

The FDA encourages patients, health care professionals, and compounders to report adverse events or quality problems through MedWatch (fda.gov/safety/medwatch).

Bottom line

FDA-approved and compounded GLP-1 medications are not interchangeable, and the FDA says compounded versions are not reviewed for safety, effectiveness, or quality. Ask direct questions and talk with a licensed provider about what's appropriate for you.